secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2021-07-20T23:59:59+00:00
Accession:  0001104659-21-093979
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven
--------------------------------------------------------------------------------

- Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.
- Product revenue $135-137M, up ~70% YoY from $80.4M; processed ~370,000 tests (+58%).
- Women's Health business achieved cash flow breakeven for the first time in Q2 2021.
- Loss from operations widened to $113-117M from $51.7M due to higher R&D and SG&A costs.
- On May 11, 2021 entered a development/option deal: paid $10M; option to buy assets for $290M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465921093979/0001104659-21-093979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465921093979/tm2115665d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-093979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer